Proton-based chemoradiation for synchronous bilateral non-small-cell lung cancers: A case report

Thoracic Cancer

Volumn 4, Issue 2, 2013, Pages 198-202

  Shi, Wenyin ^a   Nichols, Romaine C ^b   Flampouri, Stella ^b   Li, Zuofeng ^b   Hsi, Wen ^b   Huh, Soon ^b   Ho, Meng Wei ^b   Henderson, Randall H ^b   Mendenhall, Nancy P ^a,b   Hoppe, Bradford S ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Case report; Chemotherapy; Lung cancer; Proton therapy; Radiation therapy

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE; PACLITAXEL; PROTON;

AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; MALE; MEDICAL HISTORY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PERNICIOUS ANEMIA; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTON RADIATION; PROTON THERAPY; RADIATION DOSE ESCALATION; TREATMENT PLANNING; TUMOR VOLUME;

EID: 84876156416     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/j.1759-7714.2012.00141.x     Document Type: Article

References (23)

1. Shi W, Nichols RC, Flampouri S etal. Tumour shrinkage during proton-based chemoradiation for non-small-cell lung cancer may necessitate adaptive replanning during treatment. Hong Kong J Radiol 2011; 14: 190-94.
2. Zhang X, Li Y, Pan X etal. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 2010; 77: 357-66.
3. Register SP, Zhang X, Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1015-22.
4. Kadoya N, Obata Y, Kato T etal. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1225-31.
5. Hoppe BS, Huh S, Flampouri S etal. Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: a dosimetric comparison with photon-based stereotactic body radiotherapy. Radiother Oncol 2010; 97: 425-30.
6. Macdonald OK, Kruse JJ, Miller JM etal. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis. Int J Radiat Oncol Biol Phys 2009; 75: 950-58.
7. Georg D, Hillbrand M, Stock M, Dieckmann K, Pötter R. Can protons improve SBRT for lung lesions? Dosimetric considerations. Radiother Oncol 2008; 88: 368-75.
8. Chang JY, Zhang X, Wang X etal. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65: 1087-96.
9. Wang C, Nakayama H, Sugahara S, Sakae T, Tokuuye K. Comparisons of dose-volume histograms for proton-beam versus 3-D conformal x-ray therapy in patients with stage I non-small cell lung cancer. Strahlenther Onkol 2009; 185: 231-4.
10. Nichols RC, Huh SN, Henderson RH etal. Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage iii non-small-cell lung cancer: a dosimetric study. Clin Lung Cancer 2011; 12: 252-7.
11. Nichols RC, Huh SH, Hoppe BS etal. Protons safely allow coverage of high-risk nodes for patients with regionally advanced non-small-cell lung cancer. Technol Cancer Res Treat 2011; 10: 317-22.
12. Roelofs E, Engelsman M, Rasch C etal. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol 2012; 7: 165-76.
13. Hata M, Tokuuye K, Kagei K etal. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys 2007; 68: 786-93.
14. Chang JY, Komaki R, Wen HY etal. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1350-57.
15. Nakayama H, Sugahara S, Tokita M etal. Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba. Int J Radiat Oncol Biol Phys 2010; 78: 467-71.
16. Iwata H, Murakami M, Demizu Y etal. High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer. Cancer 2010; 116: 2476-85.
17. Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65: 107-11.
18. Shioyama Y, Tokuuye K, Okumura T etal. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003; 56: 7-13.
19. Bush DA, Slater JD, Bonnet R etal. Proton-beam radiotherapy for early-stage lung cancer. Chest 1999; 116: 1313-19.
20. Sejpal S, Komaki R, Tsao A etal. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 2011; 117: 3004-13.
21. Chang JY, Komaki R, Lu C etal. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 2011 (in press).
22. Hoppe BS, Flampouri S, Henderson RH etal. Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: technique and early results. Clin Lung Cancer 2012 (in press).
23. Nichols RC, Henderson RH, Huh S etal. Proton therapy for lung cancer. Thoracic Cancer 2012; 3: 109-116.